CMV retinitis is a rare but serious complication in patients undergoing daratumumab-based therapy. This case highlights the importance of ophthalmologic surveillance and flexible treatment strategies in immunocompromised patients unable to tolerate full-dose systemic antiviral agents.
Deistler et al. (Tue,) studied this question.